Although former Turing Pharmaceuticals executive Martin Shkreli’s 2015 decision to introduce a 5,000 percent price hike on a drug for a parasitic infection caused a swirl of calls for drug pricing reform, few lasting solutions have taken hold in the U.S.
After Shkreli, controversy struck over the EpiPen price hikes. The list price for two injectors reached $608.61 in 2016 from $93.88 in 2007.
Despite having been called out for huge price hikes, however, the companies haven’t been required to change the list prices for the drugs, according to a Business Insider report.
Although there are “some things in the works,” according to the report, ” … not much has been set in motion to curb the high prices patients are facing for their medications.
“We’re living in a world where financial toxicity is a real concern for patients,” U.S. Food and Drug Administration Commissioner Scott Gottlieb said. “And every member of the drug supply chain needs to take responsibility for addressing it.”